Advertisement

Topics

Latest "Boehringer Ingelheim Corporation" News Stories

01:26 EST 19th February 2019 | BioPortfolio

Here are the most relevant search results for "Boehringer Ingelheim Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Boehringer Ingelheim Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Boehringer Ingelheim Corporation for you to read. Along with our medical data and news we also list Boehringer Ingelheim Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Boehringer Ingelheim Corporation Companies for you to search.

Showing "Boehringer Ingelheim Corporation" News Articles 1–25 of 877

Extremely Relevant

Boehringer Ingelheim Partners with Epizyme

Boehringer Ingelheim and Epizyme announced a partnership on Thursday to develop oncology treatments.The partnership entails developing, researching and commercializing small molecule inhibitors directed for two epigenetics targets as potential cancer therapies. The post Boehringer Ingelheim Partners with Epizyme appeared first on Investing News Network.


Deals this week: Boehringer Ingelheim, UCB, Janssen Pharmaceutical

Boehringer Ingelheim and Domain Therapeutics have entered a deal to collaborate on a drug discovery project. Both the companies have...Read More... The post Deals this week: Boehringer Ingelheim, UCB, Janssen Pharmaceutical appeared first on Pharmaceutical Technology.

Boehringer Ingelheim inaugurates new centre for agile working methods

Boehringer Ingelheim has taken an important step towards greater agility in the company with inauguration of the new building, called "BI CUBE", at the Ingelheim site. The sustainably built and innovative building was handed over to its future users at an internal ceremony.


New patent expiration for Boehringer Ingelheim drug GLYXAMBI

Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are thirteen patents… The post New patent expiration for Boehringer Ingelheim drug GLYX... The post New patent expiration for Boehringer Ingelheim drug GLYXAMBI appeared first on Biotechblog.

New patent expiration for Boehringer Ingelheim drug JENTADUETO

Annual Drug Patent Expirations for JENTADUETO Jentadueto is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from two suppliers. There are fifteen patents… The post New patent expiration for Boehringer Ingelheim drug... The post New patent expiration for Boehringer Ingelheim drug JENTADUETO appeared first on Biotechblog.

Boehringer investiert 128 Millionen Euro am Stammsitz Ingelheim

Der Pharmakonzern Boehringer Ingelheim hat eine weitere millionenschwere Investition am Stammsitz in Ingelheim angekündigt. Für rund 128 Millionen Euro solle bis Ende 2021 ein "Neues Technikum" en...

New patent expiration for Boehringer Ingelheim drug TRADJENTA

Annual Drug Patent Expirations for TRADJENTA Tradjenta is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from two suppliers. There are thirteen patents… The post New patent expiration for Boehringer Ingelheim drug T... The post New patent expiration for Boehringer Ingelheim drug TRADJENTA appeared first on Biotechblog.

New patent expiration for Boehringer Ingelheim drug APTIVUS

Annual Drug Patent Expirations for APTIVUS Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are three patents… The post New patent expiration for Boehringer Ingelheim drug APTIVUS ... The post New patent expiration for Boehringer Ingelheim drug APTIVUS appeared first on Biotechblog.

Boehringer Ingelheim, IBM to integrate blockchain technology into clinical trials

This collaboration underscores Boehringer Ingelheim’s commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a clinical trial setting in Canada. Based The post Boehringer Ingelheim, IBM to integrate blockchain technology into clinical trials appeared first on Pharmaceutical Business review.

Positive phase III data for adalimumab biosimilar Cyltezo

Germany-based Boehringer Ingelheim Pharmaceuticals (Boehringer Ingelheim) announced on 12 September 2018 positive phase III data for its adalimumab biosimilar, Cyltezo [1]. The results, according to Boehringer Ingelheim ‘confirm that Cyltezo is equivalent to Humira, with no clinically meaningful differences in efficacy safety and immunogenicity in people with moderate-to-severe chronic plaque ps...

University of Dundee and Boehringer Ingelheim collaborate for free access of PROTAC compound on opnMe.com

Boehringer Ingelheim is to make the BET degrader compound MZ 1 available through its opnMe.com portal. The company actively supports open access in order to boost progress in biomedical and drug discovery research. MZ 1 (created at the University of Dundee) is the first external compound to be added to Boehringer Ingelheim’s’ opnMe.com portal.

Boehringer Ingelheim acquires ViraTherapeutics

ViraTherapeutics, an oncolytic virus biotech, was acquired by Boehringer Ingelheim in a bid to expand its presence in the fie -More- 

Boehringer Ingelheim and IBM Collaborate to Explore Use of Blockchain Technology in Clinical Trials

BURLINGTON, Ontario and MARKHAM, Ontario, Feb. 12, 2019 /PRNewswire/ — Boehringer Ingelheim (Canada) Ltd. and IBM Canada (NYSE: IBM) announced today at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer Ingelheim’s commitme...

Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics for €210M https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-all-viratherapeutics-shares …

Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics for €210M https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-acquires-all-viratherapeutics-shares …

Boehringer Ingelheim Acquires Viral-Based Cancer Immunotherapy Developer ViraTherapeutics

Boehringer Ingelheim has exercised its option to buy ViraTherapeutics for €210 million ($245 million), the buyer and the acquired company’s co-lead investor EMBL Ventures said today, in a deal that gives Boehringer full control over a preclinical viral-based cancer immunotherapy the companies have been co-developing for two years. EMBL Ventures is an early-stage European life science ventu...

Boehringer Ingelheim, Domain Launch CNS Drug Discovery Partnership

Boehringer Ingelheim will partner with Domain Therapeutics to discover new drugs designed to treat Central Nervous System (CNS) disorders by targeting G Protein-Coupled Receptors (GPCRs), Domain said today, through a collaboration whose value was not disclosed. Also undisclosed was how many targets the companies plan to discover. Domain said the partnership will combine its expertise […] The...

Boehringer Ingelheim (Canada) Ltd. and IBM Canada Announce First of its Kind Collaboration to Integrate Blockchain Technology into Clinical Trials

Boehringer Ingelheim (Canada) Ltd. and IBM Canada announced at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida, their plans to explore the use of blockchain technology in clinical trials. This collaboration underscores Boehringer Ingelheim's commitment to healthcare innovation and marks the first time that blockchain technology will be explored in a...

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer.  ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that ... The post Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company appeared first on Labiotech...

Distributed Bio, Boehringer Ingelheim announce SuperHuman Platform Transfer

Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce an agreement with Boehringer Ingelheim to license the Distributed Bio SuperHuman Platform for accelerating biotherapeutics discovery across therapeutic areas. “The SuperHuman Platform represents the culmination of a decade of our research in computational library de...

Boehringer plans Solids Launch Unit

Boehringer Ingelheim has broken ground for a new €85 million facility at its headquarters in Ingelheim, Germany. The Solids Launch plant, slated to start up in 2020 and employ 75 people, will focus on developing and manufacturing new tablet-form pharmaceuticals.

Boehringer Ingelheim Expands Oncolytic Virus Program and Buys ViraTherapeutics for $245 Million

Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.

Following Sanofi Cuts Last Week, Boehringer Ingelheim to Cut 327 Jobs in France

More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.

Boehringer Ingelheim axes biosimilars development outside US

Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible. BI got its biosimilar of AbbVie’s inflammatory diseases drug Humira (ad...

Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination...

Boehringer Ingelheim expands virtual clinical trials capabilities

Boehringer Ingelheim is scaling its virtual clinical trial capabilities through an agreement with the mobile technology company Science 37.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks